Eligible Groups

Only first-dose appointments are being booked at all locations at this time.

I. Super-Sites & Pop-Up Clinics

Every eligible person in Manitoba who wants to be immunized can get the COVID-19 vaccine.  But, people who are most at risk will get the vaccine first. Manitoba follows guidelines from the Government of Canada’s National Advisory Committee on Immunization (NACI), and then adapts that to our province with medical expertise and public health data. 

When it’s your turn, don’t forget to bring a signed consent form and other items from the checklist of things to bring with you (pdf) to your appointment.

You can make a vaccine appointment if you are:

  • 18 years of age and older (NEW)

When it’s your turn, don’t forget to bring a signed consent form and other items from the checklist of things to bring with you (pdf) to your appointment.

II. Medical Clinics & Pharmacies

The AstraZeneca/Covishield vaccine is provided in doctors’ offices and pharmacies. Eligible Manitobans can find their nearest clinic or pharmacy with available doses by visiting: manitoba.ca/covid19/vaccine/finder.html

Eligibility Criteria 

  • individuals aged 40 and over 
  • people aged 30 to 39 who meet one or more of the following conditions (NEW)
    • chronic renal disease including end stage renal disease undergoing hemodialysis OR peritoneal dialysis
    • chronic liver disease including cirrhosis due to any cause OR portal hypertension
    • chronic cardiovascular disease including heart failure, ventricular assist device, adult congenital heart disease coronary artery disease, malignant tachyarrythmia OR cardiomyopathies 
    • COPD, pulmonary hypertension, pulmonary fibrosis, interstitial lung disease, severe/uncontrolled asthma OR cystic fibrosis 
    • history of cerebral vascular accident with residual deficits 
    • malignant hematologic disorders including leukemia and lymphoma OR clonal blood disorder
    • malignant neoplasms (solid tissue) who will receive or are currently receiving immunosuppressive therapy including chemotherapy
    • severe obesity (BMI ≥ 40)
    • receiving one or more of the following immunosuppressive therapies: B cell therapies (e.g., rituximab, ocrelizumab), cyclophosphamide, alemtuzumab, calcineurin inhibitors, chronic dose prednisone >=20mg/day, mycophenolate, sulfasalazine and JAK inhibitors (e.g., tofacitinib)
    • solid organ or hematopoietic stem cell transplant (candidate or recipient) 
    • trisomy 21 (Down’s syndrome)
    • asplenia or hyposplenism (including sickle cell disease) 
    • chronic neurologic OR neurodevelopmental conditions including cerebral palsy, Parkinson’s disease, multiple sclerosis, ALS OR dementia (including Alzheimer’s disease) 
    • HIV (CD4 cell count ≥ 200 x 106/L and CD4 percentage ≥ 15%)
    • severe systemic autoimmune disorders (e.g., systemic lupus erythematosus, scleroderma, myocarditis, rheumatoid arthritis)
    • type 1 or 2 diabetes mellitus (poorly controlled and/or with complications)
    • active tuberculosis (current or previous) OR current latent tuberculosis (LTBI)
    • receiving other immunosuppressing therapy
    • individuals receiving home care OR receiving any level of Community Living disABILITY Services supports (or as per family physician determination of equivalent levels of family support).

III. Second Dose Eligibility

Booking for second doses will begin May 22. Initially, only people who have the following priority conditions will be able to book a second dose appointment by phone or online:

  • receiving hemodialysis OR peritoneal dialysis
  • liver cirrhosis due to any cause OR portal hypertension
  • severe heart failure 
  • cancers including solid tumor and blood (leukemia/lymphoma) who will or are receiving chemotherapy, immunosuppressive therapy or immune checkpoint inhibitors (e.g., nivolumab, pembrolizumab)
  • receiving one or more of the following medications: B cell therapies (e.g., rituximab, ocrelizumab), cyclophosphamide, alemtuzumab, calcineurin inhibitors (cyclosporine, tacrolimus), chronic dose prednisone >=20mg/day, mycophenolate, and JAK inhibitors (e.g., tofacitinib)
  • have received or are on the list to receive a solid organ transplant
  • have received a stem cell transplant OR CAR-T therapy at least 3 months ago.
  • Down syndrome
  • Human immunodeficiency virus (HIV)
  • individuals receiving home care ≥ 4 times/week OR receiving 24/7 Community Living Disability Services supports (or as per family physician determination of equivalent levels of family support).